92 related articles for article (PubMed ID: 9951552)
1. Topical application of a melanotropin analogue to vulgar vitiligo dermo-epidermal minigrafts.
Schwartzmann-Solon AM; Visconti MA; Castrucci AM
Braz J Med Biol Res; 1998 Dec; 31(12):1557-64. PubMed ID: 9951552
[TBL] [Abstract][Full Text] [Related]
2. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers.
Barnetson RS; Ooi TK; Zhuang L; Halliday GM; Reid CM; Walker PC; Humphrey SM; Kleinig MJ
J Invest Dermatol; 2006 Aug; 126(8):1869-78. PubMed ID: 16763547
[TBL] [Abstract][Full Text] [Related]
3. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation.
Falabella R; Arrunategui A; Barona MI; Alzate A
J Am Acad Dermatol; 1995 Feb; 32(2 Pt 1):228-32. PubMed ID: 7829707
[TBL] [Abstract][Full Text] [Related]
4. Transdermal delivery of a melanotropic peptide hormone analogue.
Dawson BV; Hadley ME; Kreutzfeld K; Dorr RT; Hruby VJ; Al-Obeidi F; Don S
Life Sci; 1988; 43(14):1111-7. PubMed ID: 2845208
[TBL] [Abstract][Full Text] [Related]
5. Repigmentation in vitiligo vulgaris by autologous minigrafting: results in nineteen patients.
Boersma BR; Westerhof W; Bos JD
J Am Acad Dermatol; 1995 Dec; 33(6):990-5. PubMed ID: 7490371
[TBL] [Abstract][Full Text] [Related]
6. Treatment of localized vitiligo by autologous minigrafting.
Falabella R
Arch Dermatol; 1988 Nov; 124(11):1649-55. PubMed ID: 3052304
[TBL] [Abstract][Full Text] [Related]
7. Topical application of a melanotropic peptide induces systemic follicular melanogenesis.
Hadley ME; Wood SH; Lemus-Wilson AM; Dawson BV; Levine N; Dorr RT; Hruby VJ
Life Sci; 1987 May; 40(19):1889-95. PubMed ID: 3573985
[TBL] [Abstract][Full Text] [Related]
8. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.
Sawyer TK; Sanfilippo PJ; Hruby VJ; Engel MH; Heward CB; Burnett JB; Hadley ME
Proc Natl Acad Sci U S A; 1980 Oct; 77(10):5754-8. PubMed ID: 6777774
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of the superagonist [N alpha-chlorotriazinylaminofluorescein-Ser1,Nle4,D-Phe7]-al pha-MSH.
Chaturvedi DN; Hruby VJ; Castrucci AM; Kreutzfeld KL; Hadley ME
J Pharm Sci; 1985 Mar; 74(3):237-40. PubMed ID: 2989482
[TBL] [Abstract][Full Text] [Related]
10. Calcium-dependent prolonged effects on melanophores of [4-norleucine, 7-D-phenylalanine]-alpha-melanotropin.
Hadley ME; Anderson B; Heward CB; Sawyer TK; Hruby VJ
Science; 1981 Aug; 213(4511):1025-7. PubMed ID: 6973820
[TBL] [Abstract][Full Text] [Related]
11. Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH.
Dorr RT; Dawson BV; al-Obeidi F; Hadley ME; Levine N; Hruby VJ
Invest New Drugs; 1988 Dec; 6(4):251-8. PubMed ID: 2852652
[TBL] [Abstract][Full Text] [Related]
12. Behavioral effects of [4-norleucine, 7-D-phenylalanine]-alpha-melanocyte-stimulating hormone.
Kobobun K; O'Donohue TL; Handelmann GE; Sawyer TK; Hruby VJ; Hadley ME
Peptides; 1983; 4(5):721-4. PubMed ID: 6657517
[TBL] [Abstract][Full Text] [Related]
13. Administration of melanotropic peptides during gestation in the rodent.
Dawson BV; Ford CA; Holloway H; Dorr RT; Johnson P
Toxicology; 1993 Jan; 77(1-2):91-101. PubMed ID: 8382846
[TBL] [Abstract][Full Text] [Related]
14. In vitro transdermal delivery of a melanotropic peptide through human skin.
Dawson BV; Hadley ME; Levine N; Kreutzfeld KL; Don S; Eytan T; Hruby VJ
J Invest Dermatol; 1990 Apr; 94(4):432-5. PubMed ID: 2155969
[TBL] [Abstract][Full Text] [Related]
15. Cyclic lactam analogues of Ac-[Nle4]alpha-MSH4-11-NH2.
Sugg EE; Castrucci AM; Hadley ME; van Binst G; Hruby VJ
Biochemistry; 1988 Oct; 27(21):8181-8. PubMed ID: 2852955
[TBL] [Abstract][Full Text] [Related]
16. Transplantation of autologous minigrafts for the treatment of stable vitiligo.
Sun X; Qian G; Wu Y; Shen H; Wang T; Hu J; Guo B; Wu J; Xu A
J Dermatolog Treat; 2012 Apr; 23(2):122-7. PubMed ID: 21254850
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.
Grimes PE; Hamzavi I; Lebwohl M; Ortonne JP; Lim HW
JAMA Dermatol; 2013 Jan; 149(1):68-73. PubMed ID: 23407924
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.
Minder EI; Barman-Aksoezen J; Schneider-Yin X
Clin Pharmacokinet; 2017 Aug; 56(8):815-823. PubMed ID: 28063031
[TBL] [Abstract][Full Text] [Related]
19. Prolonged stimulation of S91 melanoma tyrosinase by [Nle4, D-Phe7]-substituted alpha-melanotropins.
Abdel Malek ZA; Kreutzfeld KL; Marwan MM; Hadley ME; Hruby VJ; Wilkes BC
Cancer Res; 1985 Oct; 45(10):4735-40. PubMed ID: 2992767
[TBL] [Abstract][Full Text] [Related]
20. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation.
Westerhof W; Boersma B
J Am Acad Dermatol; 1995 Dec; 33(6):1061-2. PubMed ID: 7490361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
